Patents Assigned to VYLUMA INC.
-
Publication number: 20240342154Abstract: The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.Type: ApplicationFiled: June 26, 2024Publication date: October 17, 2024Applicant: Vyluma Inc.Inventors: Navneet Puri, Prem Sagar Akasapu, Irfan Ali Mohammed, Kumaresh Soppimath, Iouri V. Ilitchev
-
Patent number: 12036217Abstract: The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.Type: GrantFiled: June 28, 2023Date of Patent: July 16, 2024Assignee: VYLUMA INC.Inventors: Navneet Puri, Prem Sagar Akasapu, Irfan Ali Mohammed, Kumaresh Soppimath, Iouri V. Ilitchev
-
Publication number: 20240156724Abstract: A sterile multi-dose ophthalmic consumer product, and especially a multi-dose low-concentration atropine eye drop container is disclosed having desirable atropine stability, low loss of viscosity, and low levels of total impurities leached from the container even after extended storage in the container.Type: ApplicationFiled: March 14, 2022Publication date: May 16, 2024Applicants: Vyluma Inc., Vyluma Inc.Inventors: Kumaresh Soppimath, Tushar Hingorani, Hari A. Attluri
-
Publication number: 20230355604Abstract: The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.Type: ApplicationFiled: June 28, 2023Publication date: November 9, 2023Applicant: Vyluma Inc.Inventors: Navneet Puri, Prem Sagar Akasapu, Irfan Ali Mohammed, Kumaresh Soppimath, Iouri V. Ilitchev
-
Publication number: 20230301993Abstract: Ophthalmic formulations for treatment of night vision disturbance syndrome (NVD) are presented and preferably comprise brimonidine, rivastigmine, and/or galantamine at very low concentrations. Such formulations unexpectedly provided acute and transient therapeutic effect to alleviate one or more symptoms associated with NVD.Type: ApplicationFiled: July 23, 2021Publication date: September 28, 2023Applicant: Vyluma Inc.Inventors: Jack Martin Lipman, Kumaresh Soppimath, Tushar Hingorani
-
Patent number: 11730727Abstract: The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.Type: GrantFiled: August 31, 2020Date of Patent: August 22, 2023Assignee: VYLUMA INC.Inventors: Irfan A. Mohammed, Tushar Hingorani, Kumaresh Soppimath
-
Patent number: 11730728Abstract: The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.Type: GrantFiled: August 31, 2020Date of Patent: August 22, 2023Assignee: VYLUMA INC.Inventors: Irfan A. Mohammed, Tushar Hingorani, Kumaresh Soppimath
-
Patent number: 11707458Abstract: The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.Type: GrantFiled: September 9, 2020Date of Patent: July 25, 2023Assignee: VYLUMA INC.Inventors: Irfan A. Mohammed, Tushar Hingorani, Kumaresh Soppimath
-
Patent number: 11642338Abstract: The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.Type: GrantFiled: January 11, 2021Date of Patent: May 9, 2023Assignee: VYLUMA INC.Inventors: Kumaresh Soppimath, Tushar Hingorani
-
Patent number: 11464769Abstract: The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.Type: GrantFiled: July 20, 2020Date of Patent: October 11, 2022Assignee: VYLUMA INC.Inventors: Navneet Puri, Prem Sagar Akasapu, Irfan A. Mohammed, Kumaresh Soppimath, Iouri V. Ilitchev
-
Publication number: 20220160674Abstract: Ophthalmic formulations for acute and transient treatment of night vision disturbance syndrome (NVD) are presented. Preferred formulations comprise carbachol at very low concentrations that were demonstrated to unexpectedly provide an acute and transient therapeutic effect for a desirable magnitude and period of time.Type: ApplicationFiled: February 3, 2022Publication date: May 26, 2022Applicant: Vyluma Inc.Inventors: Jack Martin Lipman, Tushar Hingorani, Kumaresh Soppimath
-
Patent number: 11273141Abstract: Ophthalmic formulations for acute and transient treatment of night vision disturbance syndrome (NVD) are presented. Preferred formulations comprise carbachol at very low concentrations that were demonstrated to unexpectedly provide an acute and transient therapeutic effect for a desirable magnitude and period of time.Type: GrantFiled: May 18, 2021Date of Patent: March 15, 2022Assignee: VYLUMA INC.Inventors: Jack Martin Lipman, Tushar Hingorani, Kumaresh Soppimath
-
Publication number: 20210353584Abstract: Ophthalmic formulations for acute and transient treatment of night vision disturbance syndrome (NVD) are presented. Preferred formulations comprise carbachol at very low concentrations that were demonstrated to unexpectedly provide an acute and transient therapeutic effect for a desirable magnitude and period of time.Type: ApplicationFiled: May 18, 2021Publication date: November 18, 2021Applicant: VYLUMA INC.Inventors: Jack Martin Lipman, Tushar Hingorani, Kumaresh Soppimath
-
Patent number: RE50040Abstract: The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.Type: GrantFiled: March 2, 2022Date of Patent: July 16, 2024Assignee: VYLUMA INC.Inventors: Navneet Puri, Prem Sagar Akasapu, Irfan A. Mohammed, Kumaresh Soppimath, Iouri V. Ilitchev
